Literature DB >> 24880541

Glycine receptor antibodies in a boy with focal epilepsy and episodic behavioral disorder.

Eva Wuerfel1, Christian G Bien2, Angela Vincent3, Mark Woodhall3, Knut Brockmann4.   

Abstract

A wide range of clinical presentations including neuromuscular disorders and autoimmune encephalopathies is being recognized to be associated with various autoantibodies. Glycine receptor (GlyR) antibodies have so far been found mainly in adult patients with phenotypes comprising progressive encephalomyelitis with rigidity and myoclonus or stiff-person syndrome. We report a four-year-old boy who presented with a two-year-history of drug-resistant focal epilepsy with unusual seizure semiology, temper tantrums, headache, clumsiness, and intermittently impaired speech. While MRI and CSF were normal, screening for autoimmune antibodies revealed GlyR antibodies in serum. Immunomodulatory treatment with steroids resulted in rapid and complete resolution of symptoms. Our observation widens the spectrum of clinical presentations associated with GlyR antibodies and emphasizes the potential relevance of neuronal autoantibodies in epilepsies of unknown cause in children as well as in adults.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune antibodies; Children; Encephalopathy; Epilepsy; Partial Seizures; Stiff-person syndrome

Mesh:

Substances:

Year:  2014        PMID: 24880541     DOI: 10.1016/j.jns.2014.05.014

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  Neuronal surface antibody-mediated autoimmune encephalitis.

Authors:  Jenny J Linnoila; Myrna R Rosenfeld; Josep Dalmau
Journal:  Semin Neurol       Date:  2014-11-04       Impact factor: 3.420

Review 2.  Neuronal central nervous system syndromes probably mediated by autoantibodies.

Authors:  Aude Chefdeville; Jérôme Honnorat; Christiane S Hampe; Virginie Desestret
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

3.  Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis.

Authors:  Divyanshu Dubey; Zehra Farzal; Ryan Hays; L Steven Brown; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2016-07-04       Impact factor: 6.570

4.  Glycine receptor antibody-associated epilepsy in a boy aged 4 years.

Authors:  Chinwe Ude; Gautam Ambegaonkar
Journal:  BMJ Case Rep       Date:  2016-10-19

Review 5.  Clinical Spectrum of Stiff Person Syndrome: A Review of Recent Reports.

Authors:  Harini Sarva; Andres Deik; Aman Ullah; William L Severt
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-03-04

Review 6.  Innate and adaptive immunity in human epilepsies.

Authors:  Jan Bauer; Albert J Becker; Wassim Elyaman; Jukka Peltola; Stephan Rüegg; Maarten J Titulaer; James A Varley; Ettore Beghi
Journal:  Epilepsia       Date:  2017-07       Impact factor: 5.864

7.  A brain proteomic investigation of rapamycin effects in the Tsc1+/- mouse model.

Authors:  Hendrik Wesseling; Ype Elgersma; Sabine Bahn
Journal:  Mol Autism       Date:  2017-08-01       Impact factor: 7.509

8.  Plasma Amino Acid Profile in Patients with Aortic Dissection.

Authors:  Linlin Wang; Sha Liu; Wengang Yang; Haitao Yu; Li Zhang; Ping Ma; Peng Wu; Xue Li; Kenka Cho; Song Xue; Baohong Jiang
Journal:  Sci Rep       Date:  2017-01-10       Impact factor: 4.379

Review 9.  Antiglycine receptor antibody related disease: a case series and literature review.

Authors:  A Swayne; L Tjoa; S Broadley; S Dionisio; D Gillis; L Jacobson; M R Woodhall; A McNabb; D Schweitzer; B Tsang; A Vincent; S R Irani; R Wong; P Waters; S Blum
Journal:  Eur J Neurol       Date:  2018-07-21       Impact factor: 6.089

Review 10.  Relevance of Surface Neuronal Protein Autoantibodies as Biomarkers in Seizure-Associated Disorders.

Authors:  Gabriela Dumitrita Stanciu; Veronica Bild; Daniela Carmen Ababei; Razvan Nicolae Rusu; Sorin Ioan Beschea Chiriac; Elena Rezuş; Andrei Luca
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.